The mammalian genome contains four voltage-gated sodium channel genes that are primarily expressed in the central nervous system: SCN1A, SCN2A, SCN3A and SCN8A. Mutations in SCN1A and SCN2A are responsible for several dominant idiopathic epilepsy disorders, including generalized epilepsy with febrile seizures plus (GEFS1) and severe myoclonic epilepsy of infancy (SMEI). Mutations in SCN8A are associated with cognitive deficits and neuropsychiatric illness in humans and movement disorders in mice; however, a role for SCN8A (Na v 1.6) in epilepsy has not been investigated. To determine the relationship between Na v 1.6 dysfunction and seizure susceptibility, we examined the thresholds of two Scn8a mouse mutants, Scn8a med and Scn8a med-jo , to flurothyl-and kainic acid (KA)-induced seizures. Both mutants were more seizure resistant than wild-type littermates, suggesting that altered Na v 1.6 function reduces neuronal excitability. To determine whether impaired Na v 1.6 function could ameliorate seizure severity in a mouse model of SMEI, we generated Scn1a 1/2 ; Scn8a med-jo/1 double heterozygous mice. Unlike Scn1a 1/2 mice that are more susceptible to flurothyl-induced seizures, Scn1a 1/2 ; Scn8a med-jo/1 mice displayed thresholds that were comparable to wildtype littermates. The Scn8a med-jo allele was also able to rescue the premature lethality of Scn1a 1/2 mice and extend the lifespan of Scn1a 2/2 mutants. These results demonstrate that genetic interactions can alter seizure severity and support the hypothesis that genetic modifiers contribute to the clinical variability observed in SMEI and GEFS1.
INTRODUCTION
Voltage-gated sodium channels are transmembrane protein complexes that play a critical role in electrical signaling between cells. Following an initial membrane depolarization, voltage-gated sodium channels open, permitting the rapid influx of sodium ions and the initiation and propagation of an action potential. Voltage-gated sodium channels are comprised of one a subunit and one or more auxiliary b subunits (b1-b4). The 260 kDa a subunit contains several functional domains including an ion selective pore, an intracellular inactivation gate, and a positively charged voltage sensor (1) .
The human genome contains 9 voltage-gated sodium channel a subunit genes, each with distinct spatial and temporal expression patterns (2) . Four a subunits, Na v 1.1, Na v 1.2, Na v 1.3 and Na v 1.6, respectively encoded by SCN1A, SCN2A, SCN3A and SCN8A, are primarily expressed in the central nervous system (3) (4) (5) . Mutations in SCN1A and SCN2A cause several subtypes of dominant idiopathic generalized epilepsy. Mutations in both SCN1A and SCN2A lead to generalized epilepsy with febrile seizures plus (GEFSþ; MIM 604233) (6, 7) . SCN2A dysfunction also causes benign familial neonatal-infantile seizures (BFNIS; MIM 607745) (8) , while SCN1A mutations are the main cause of severe myoclonic epilepsy of infancy (SMEI; MIM 607208) (9) . SMEI is a debilitating form of childhood epilepsy characterized by complex febrile seizures, the development of afebrile seizures, and mental retardation. SMEI often results from loss of function # The Author 2007. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org SCN1A mutations, and represents a haploinsufficiency phenotype (10) . Affected members of GEFSþ families with the same SCN1A mutation often present with a variety of epilepsy subtypes and severities, ranging from childhood febrile seizures to adult generalized or partial epilepsy to SMEI (11, 12) . Variable clinical severities are also observed among sporadic SMEI patients.
Yu et al. (13) constructed a mouse model of SMEI by targeted disruption of the mouse Scn1a gene. Heterozygous Scn1a þ/2 mutants, expressing 50% of normal Na v 1.1 channel levels, exhibit spontaneous seizures and a high mortality rate from 4 weeks after birth. Homozygous mutants, which completely lack Na v 1.1 channels, are ataxic and die 15 days after birth. Electrophysiological analysis of hippocampal pyramidal neurons from Scn1a 2/2 mice revealed normal levels of sodium currents, indicating that Scn1a 2/2 does not make a major contribution to sodium currents in these neurons. In contrast, sodium currents were significantly reduced in hippocampal interneurons that are critical for GABA-mediated neuronal inhibition. The ataxia observed in homozygous Scn1a 2/2 mutants is thought to be caused by reduced peak, persistent and resurgent sodium current in cerebellar Purkinje neurons (14) . A second mouse model of SMEI was recently generated by the targeted introduction of a premature stop codon (R1407X), identified in three SMEI patients, into the mouse Scn1a gene (15) . These heterozygous mutants also displayed decreased Na v 1.1 expression, spontaneous seizures, and abnormal firing of neocortical interneurons. Both studies therefore suggest that reduced neuronal inhibition contributes to the SMEI phenotype.
The first mutation in the human SCN8A gene, encoding Na v 1.6 channels, was recently reported in a proband with juvenile-onset ataxia and mental retardation. Additional family members with the same dominant mutation displayed mild cognitive deficits and a variety of behavioral abnormalities (16) . In the mouse, recessive mutations in Scn8a result in neuromuscular disorders. Mice homozygous for a point mutation in Scn8a (Scn8a med-jo ) display cerebellar ataxia and a tremor involving the head and body (17) (18) (19) . Homozygosity for null mutations of Scn8a (Scn8a med or Scn8a
med-tg
) results in progressive paralysis, muscular atrophy of the hind limbs, and premature death between 3 and 4 weeks of age (20) (21) (22) (23) . In addition, mice that lack Scn8a only in cerebellar Purkinje neurons exhibit impaired learning when examined using the Morris water maze (24) .
A number of studies have examined the neuromuscular phenotypes of the Scn8a mutant mice; however, the effect of Na v 1.6 dysfunction on seizure thresholds has not been investigated. To determine if Na v 1.6 dysfunction leads to altered seizure thresholds, we examined the thresholds of heterozygous Scn8a med/þ and Scn8a med-jo/þ mice to seizures induced by the chemiconvulsants flurothyl and KA. In addition, we explored possible genetic interactions between Scn1a and Scn8a by analyzing the seizure thresholds and lifespan of Scn1a þ/2 ; Scn8a med-jo/þ double heterozygous mutants.
RESULTS

Na v 1.6 dysfunction increases seizure thresholds
To examine the effect of Na v 1.6 dysfunction on seizure thresholds, Scn8a med/þ , Scn8a med-jo/þ , and wild-type littermates were exposed to flurothyl, a chemiconvulsant thought to inhibit GABA-mediated neurotransmission ( Fig. 1) (25) . The latency to the myoclonic jerk (MJ), the first observable behavioral response, and the latency to the generalized tonicclonic seizure (GTCS) were measured. Latencies to the MJ and the GTCS were increased by 25% (P = 2.0 Â 10 24 ) and 58% (P = 8.1 Â 10 27 ), respectively, in Scn8a med/þ mutants when compared to wild-type littermates (Fig. 1A) . Similarly, Scn8a med-jo/þ mice showed a 31% increase (P = 4.4 Â 10
27
) in the latency to the MJ and a 55% increase (P = 1.4 Â 10
26
) in the latency to the GTCS (Fig. 1B) , indicating that the Scn8a mutants are more resistant to flurothyl-induced seizures.
Seizure thresholds in response to KA, a kainate glutamate receptor agonist, were also assessed in Scn8a med/þ and Scn8a med-jo/þ mice (Fig. 2) . Seizure severity was measured using a modified Racine scale in which a score of 0 indicates no response and a score of 6 indicates death (26) . At a dose of 20 mg/kg KA, Scn8a med/þ mice progressed to an average seizure severity of 3.0, and no GTCS was observed. In contrast, wild-type littermates progressed to an average seizure severity of 5.0 (P=0.009), with 80% exhibiting a GTCS (P = 7.1 Â 10 24 ) ( Fig. 2A) . Scn8a med/þ mice also displayed a trend toward increased seizure resistance at a dose of 30 mg/kg KA; however, the measured parameters were not statistically different when compared to wild-type littermates (data not shown). At a dose of 20 mg/kg KA, Scn8a med-jo/þ mutants progressed to an average seizure severity of 4.5, with 50% exhibiting a GTCS. Wild-type littermates reached an average seizure severity of 5.4 (P = 0.37), with 80% exhibiting a GTCS (P = 0.20) (Fig. 2B) . The average seizure severity score of the Scn8a med-jo/þ mutants reflected a similar trend (P = 0.19) consistent with increased seizure resistance at a dose of 15 mg/kg KA (data not shown).
Na v 1.6 dysfunction restores normal seizure thresholds in a mouse model of SMEI A mouse model of SMEI was recently generated by targeted deletion of the mouse Scn1a gene (13) . Scn1a þ/2 mutants exhibit spontaneous tonic-clonic seizures and reduced lifespan. In order to investigate whether the increased seizure resistance associated with Na v 1.6 dysfunction could ameliorate the SMEI phenotype, we compared the thresholds to flurothyl-induced seizures in Scn1a þ/2 mice to Scn1a þ/2 ; Scn8a med-jo/þ double heterozygous mutants. The latency to the MJ in Scn1a þ/2 mutants was not statistically different from wild-type littermates (Fig. 3A ). In contrast, the latency to the GTCS was reduced by 27% (Scn1a þ/2 , 4.46 + 1.19 min; wild-type, 6.13 + 0.69 min; P = 0.0049) (Fig. 3B ). Scn1a þ/2 mice also displayed a more severe response with 62% of Scn1a þ/2 mutants progressing to tonic hind-limb extension following the GTCS, compared to only 9% of the wild-type littermates (P = 0.043) ( Table 1 ). The latency to the MJ and the GTCS were increased by 39% (P = 0.0034) and 45% (P = 0.0017) in Scn1a þ/2 ; Scn8a med-jo/þ mutants when compared to Scn1a þ/2 littermates ( Fig. 3A and B) . Thresholds to the GTCS in the double heterozygous mutants were comparable to that of wild-type littermates (Scn1a þ/2 ; Scn8a med-jo/þ , 6.46 + 0.65 min; wild-type, 6.12 + 0.41 min; P = 0.31) (Fig. 3B ). The percentage of mice progressing to tonic hind-limb extension following the Human Molecular Genetics, 2007, Vol. 16, No. 23 2893 GTCS was reduced from 63% in Scn1a þ/2 mice to 0% in Scn1a þ/2 ; Scn8a med-jo/þ mice (P = 0.026), which was similar to the incidence in wild-type littermates ( Table 1) . The increased threshold to flurothyl-induced GTCS and the reduced severity of the seizure response demonstrates that the Scn8a med-jo/þ mutation can rescue the seizure susceptibility of Scn1a þ/2 mice.
The Scn8a med-jo mutation rescues the premature lethality of heterozygous Scn1a 1/2 mice
To determine if the Scn8a med-jo mutation could also improve the survival of Scn1a þ/2 mice, we compared the lifespan of
mutants were examined for 150 days from birth. During this time period we observed frequent spontaneous generalized seizures in the Scn1a þ/2 mice. A mortality rate of 40 and 100% at postnatal days 50 (P50) and 125 (P125) were noted for the Scn1a þ/2 mice. In contrast, no visible seizures or death was observed in Scn1a þ/2 ; Scn8a med-jo/þ mice during the 150 day observation period (Fig. 4A) .
To confirm that the increased lifespan of the double heterozygous mutants was due to reduced seizure activity, we examined the electrocorticogram (ECoG) pattern of wild-type, Scn1a þ/2 , and Scn1a þ/2 ; Scn8a med-jo/þ littermates (Fig. 5 ). ECoGs were recorded from 8 to 10 week-old freely moving mice. Scn1a þ/2 mice display ictal polyspike activity accompanied by stereotypic seizure behaviors with a typical duration of 15 -30 s (Fig. 5B) (13) . Scn1a þ/2 ; Scn8a med-jo/þ mutants displayed frequent generalized spike and wave discharges that were associated with behavioral arrest. The average occurrences of the discharges in the Scn1a þ/2 ; Scn8a med-jo/þ mutants were 35 and 50 per hour during the light and dark cycles, respectively. The frequencies of the discharges ranged from 2.3 to 12 Hz, with the majority of discharges occurring between 5 -6 Hz. Unlike the ictal polyspike activity observed in the Scn1a þ/2 mice, the spike and wave discharges in the double heterozygous mutants were typically much shorter in duration (2 -3 s) and did not involve a behavioral component (Fig. 5C ). These brief spike and wave discharges were not observed in Scn1a þ/2 mice (13). 
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P15 (P=0.003).
Three mutants died at P15, two at P16, three at P17, and one at P18 (Fig. 4B) . Although the presence of the Scn8a med-jo allele was unable to rescue the premature lethality of Scn1a 2/2 mice, it was able to modestly improve lifespan.
DISCUSSION
Mutations in SCN1A cause several dominant idiopathic generalized epilepsy syndromes including GEFSþ and SMEI. A prominent feature of both GEFSþ and SMEI is the variable severity of the disease phenotype. Family members carrying the same GEFSþ mutation display phenotypes ranging from childhood febrile seizures to mild or severe adult afebrile epilepsy to SMEI (11, 12) . This variable clinical presentation within a family suggests that genetic and/or environmental factors may modify the severity of the GEFSþ and SMEI phenotypes.
Although it is widely accepted that the clinical presentation of a disease can be influenced by genetic modifiers, only a small number of human modifier genes have been identified (27 -29) . Studies conducted in mice with sodium channel mutations, including the Scn2a Q54 , Scn8a medJ and Scn1a loss of function mutants, have demonstrated that their phenotypes can be influenced by genetic modifiers (15,30 -32) . Genetic modifiers that influence the seizure phenotype of the Scn2a Q54 mutant have been localized to chromosomes 11 and 19 (30) . The phenotype of Scn2a Q54 mice can also be altered by the Szt1 or Nmf134 mutant alleles of the potassium channel Kcnq2. Double heterozygous mutants carrying the
Scn2a
Q54 transgene and either Kcnq2 mutation display a more severe phenotype characterized by early onset generalized epilepsy and juvenile lethality at 3 weeks of age (33) . A dramatic example of genetic modification is provided by homozygous Scn8a medJ mutants. When maintained on a C57BL/6J background, homozygous Scn8a medJ mutants exhibit premature lethality by 4 weeks of age. In contrast, on genetic backgrounds that carry a functional copy of the dominant genetic modifier Scnm1, Scn8a medJ mutants exhibit a normal lifespan (31, 32) . Here, we demonstrate that Scn8a can function as a modifier in a mouse model of SMEI by restoring normal seizure thresholds and improving survival. These results provide evidence for genetic modification as a mechanism by which SMEI and possibly GEFSþ phenotypes can be altered, and further supports the notion that genetic variants in one ion channel can modify the phenotype caused by a deleterious mutation in another ion channel.
Mutations in the mouse Scn8a gene result in a variety of recessive neuromuscular phenotypes, including tremor, cerebellar ataxia, dystonia and paralysis. The tremor and ataxia are believed to result from the altered biophysical properties of Purkinje cells (34, 35) . Purkinje cells of homozygous Scn8a mutants display reduced persistent current, reduced resurgent current and diminished spontaneous simple spikes (34, 36, 37) . In addition, prefrontal cortex pyramidal cells and retinal ganglion cells of the homozygous Scn8a med mutants also show reduced excitability (38, 39) . Scn8a med-jo/þ and Scn8a med/þ mutants exhibited comparable increases in thresholds to flurothyl-induced seizures, while Scn8a med/þ mice appeared to exhibit higher thresholds to KA-induced seizures. Electrophysiological analysis of Purkinje cells from homozygous Scn8a med and Scn8a med-jo mice revealed more pronounced defects in persistent, transient and resurgent sodium currents in the Scn8a med mutants (37) . The higher threshold to KA-induced seizures observed in Scn8a med/þ mice may therefore reflect a larger effect of this mutation on neuronal excitability. However, we cannot rule out that the possibility that differences in genetic backgrounds may have contributed to this observation, since the Scn8a med and Scn8a med-jo/þ mice are maintained on the C3HeB/FeJ and C57BL/6J genetic backgrounds, respectively. In addition, loss of function Scn8a mutations, such as Scn8a med , result in cell-specific compensatory changes in which Na v 1.1 or Na v 1.2 channels accumulate at the nodes of Ranvier and initial segments of the cerebellum, optic nerve, cortex, and hippocampus (39) . As a result, redistribution or up-regulation of sodium channel subunits in the Scn8a med/þ mutant may have also contributed to the higher threshold to KA-induced seizures.
Lower seizure thresholds and spontaneous seizures are observed in mice with reduced Scn1a expression. In contrast,
Scn8a
med/þ mutants with reduced Scn8a expression display elevated seizure thresholds. We hypothesize that the opposing effects of Na v 1.1 and Na v 1.6 dysfunction on seizure thresholds are due to differences in the cell types that are influenced by these sodium channel subtypes. Support for this hypothesis is derived from the observation that GABAergic interneurons of the hippocampus and cortex, but not excitatory pyramidal cells, have reduced sodium currents in Scn1a þ/2 and Scn1a ; n = 9-13 per group.
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Human Molecular Genetics, 2007, Vol. 16, No. 23 mutants (13, 15) . In addition, Na v 1.1 channels preferentially localize to the soma and axons of parvalbumin-positive interneurons in the hippocampus and neocortex (15) . These findings suggest that the reduced excitability of interneurons in the cortex and hippocampus contribute to seizure generation in SMEI. In contrast, excitatory neuronal cell types, such as Purkinje cells, pyramidal cells of the cortex and retinal ganglion cells, are affected in Scn8a mutants. Therefore, reduced excitability of pyramidal cells in the hippocampus and cortex in Scn8a mutants may underlie the elevated seizure resistance of these mice. The Scn8a med-jo allele was also capable of restoring normal thresholds to flurothyl-induced seizures in Scn1a þ/2 ; Scn8a med-jo/þ double heterozygous mice. Since the mechanism of action of flurothyl is not fully understood, we also evaluated the double heterozygous mutants for more physiologically relevant indicators of improved neuronal excitability. Unlike Scn1a þ/2 mice that display frequent spontaneous seizures with stereotypic motor behaviors and a reduced lifespan, no mortality or seizures were observed in the double heterozygous mutants. Scn1a þ/2 mutants also display excessive jumping and erratic behavior in response to mild startle. Whether this hyper-responsive behavior reflects seizure activity is unclear; however, this behavioral abnormality was not observed in the double heterozygous mutants.
In the presence of the Scn8a med-jo allele, a modest improvement in the lifespan of Scn1a 2/2 mice was also observed. Interestingly, the increase in lifespan is similar to that achieved by manual feeding of Scn1a 2/2 mutants (13). The incomplete rescue of the premature lethality of Scn1a 2/2 mice suggests that there is a limit to the magnitude of the abnormal neuronal excitability that can be corrected by altered Na v 1.6 function. It is also possible that the level of expression of Scn8a in neonatal pups may be insufficient to restore normal neuronal excitability in pups that lack Na v 1.1 channels. Alternatively, Na v 1.1 channels may play a unique role in one or more biological processes that are necessary for survival. Consistent with this possibility is the observation that SCN1A mutations in humans are dominant and individuals with two mutant SCN1A alleles have not been identified.
The findings of this study indicate that Scn8a can function as a genetic modifier of SMEI. Together with previous studies showing genetic interactions between Scn2a and Kcnq2 in mouse epilepsy (32), our results support the idea that genetic testing for mutations and single nucleotide polymorphisms in a panel of selected ion channel genes might provide useful clinical information to guide treatment of generalized epilepsy. Furthermore, our results suggest that blocking Na v 1.6 channels may be one of the therapeutic benefits of currently used non-selective sodium channelblocking anti-epileptic drugs, and raises the possibility that selective blocking of Na v 1.6 channels may improve efficacy in patients with epilepsy. Although pharmacological agents that can selectively target sodium channel subtypes are currently unavailable, new methodologies, such as the development of siRNAs against SCN8A, may enable the selective targeting of Na v 1.6 channels in the future. Additional studies using mice with different forms of epilepsy will also provide the opportunity to evaluate the ability of Scn8a to ameliorate seizure severity in more common types of epilepsy. med-jo/þ , 12% wild-type). Littermates were used for all experiments to minimize variation due to differences in genetic backgrounds. Mice were reared in a pathogen-free mouse facility with a 12 h light/dark cycle. Food and water were available ad libitum. All experimental protocols involving mice were approved by the Emory University IACUC committee.
MATERIALS AND METHODS
Animals
Genotyping of mice
Scn1a mutants were genotyped using primers pairs specific to the neomycin cassette; NF (AGGATCTCCTGTCATCT CACCTTGCTCCTG), NR (AAGAACTCGTCAAGAAGGC GATAGAAGGCG) and to Scn1a exon 26; 1aF (CGAATC CAGATGGAAGAGCGGTTCATGGCT), 1aR (ACAAGCTG CTATGGACATTGTCAGGTCAGT). A 290 bp PCR product was generated from the wild-type allele and a 490 bp PCR product was generated from the mutant allele using the primer pairs 1aF, 1aR and NF, NR, respectively. PCR amplification was carried out with one cycle at 948C for 2 min and 32 cycles of 948C for 30 s, 608C for 30 s, and 728C for 45 s. Genotyping of C3HeB/FeJ-Scn8a med /J mice was performed with PCR primers and conditions suggested by the Jackson Laboratory (http://jaxmice.jax.org/pub-cgi/protocols/protocols. sh?objtype=protocol&protocol_id=454).
Genotyping of C57BL/6J-Scn8a med-jo /J mice was performed using primer pair, 8aF (ATGCCACAGAAGTGTCATTCC) and 8aR (GGTATTTCCCAGCAAACAGGT). PCR amplification was performed with one cycle at 948C for 2 min and 32 cycles of 948C for 30 s, 558C for 30 s and 728C for 30 s. The 204 bp PCR product was digested with MslI to produce a 129 bp fragment from the wild-type allele and a 102 bp fragment from the mutant allele.
Flurothyl seizure induction
Mice between 5 and 12 weeks of age were placed in a clear plexiglass chamber, and flurothyl (2,2,2-trifluroethylether) (Sigma-Aldrich) was slowly introduced into the chamber via a syringe pump at a rate of 20 ml/min and allowed to volatilize. Seizure thresholds were determined by measuring the latency to the first MJ and to the GTCS. The MJ is the first observable behavioral response, and is characterized by a brief jerk of the shoulders and/or neck. The GTCS is characterized by convulsions of the entire body and a loss of posture. The mice were also scored for progression of the GTCS to tonic hind-limb extension. Data from males and females were analyzed separately. No sex differences in the data were observed; therefore, the data from both sexes were combined.
KA seizure induction
Mice between 3 and 4 months of age were injected intraperitoneally (i.p.) with 15, 20 or 30 mg/kg KA (Ocean Produce International). KA was dissolved in 0.9% saline to a concentration of 2.5 mg/ml in order to obtain an appropriate injection volume. All mice were injected between 12 noon and 4 p.m. to minimize behavioral variation due to the circadian rhythm. After the injection of KA, mice were observed for 2 h and scored according to a modified Racine scale (26) . This modified scale is based on the following criteria: stage 0 -no response; stage 1 -staring; stage 2 -head nodding; stage 3 -forelimb clonus; stage 4 -rearing and falling; stage 5 -GTCS; stage 6 -death. Data from males and females were analyzed separately. No sex differences in the data were observed; therefore, the data from both sexes were combined.
Statistical analysis
For parametric data sets, statistical analysis between genotypes was performed using the Student t-test. Dichotomous data sets (the number of mice exhibiting a GTCS and the mortality rates) were analyzed for statistical significance using the Fisher Exact test, while non-parametric data (the KA seizure stage) was analyzed using a Mann -Whitney Rank Sum test.
Electrocorticography
Wild-type, Scn1a þ/2 , and Scn1a þ/2 ; Scn8a med-jo mice were implanted for ECoG recordings. Briefly, mice were anesthetized with isoflurane gas and placed onto a stereotaxic frame (Cartesian Research, OR, USA). Two pairs of bipolar stainless steel screws were placed ipsilaterally for ECoG monitoring. One pair on the right hemisphere (anteroposterior (AP) = þ 2.00 mm from bregma, mediolateral (ML) = þ 1.00 mm from midline; AP = 2 1.5 mm from bregma, ML = þ 1.0 mm from midline) and the other pair on the left hemisphere (AP = 2 0.5 mm from bregma, ML = 2 2.2 mm from midline; AP = 2 3.5 mm from bregma, ML = 2 2.2 mm from midline). In addition, two fine wires (Cooner AS632, CA, USA) were inserted into the dorsal neck muscles to facilitate recording of muscle activity. ECoG and electromyogram (EMG) electrodes were attached to a micro-connector (VMS, OH, USA), and dental ceramic compound was poured over the screws, wires and base of the skullcap.
After 3 days of recovery, each mouse was placed into a Plexiglas box (15 cm Â 15 cm Â 15 cm) and was attached to a series of bioelectric amplifiers (Embla A10, Iceland) via a small counterbalanced commutator (Dragonfly Research, WV, USA). Following 24 h of acclimatization, ECoG and EMG data were collected for 96 h. Amplified ECoG and EMG signals were digitally collected, processed and viewed in real-time with the Somnologica Science rodent sleep-recording software package (Iceland). Epileptiform activity was manually scored.
